文献速递胸部肿瘤放疗放疗物理与技术

早期非小细胞肺癌剂量递增质子治疗Ⅰ/Ⅱ期研究长期结果

Long-term outcome of phase I/II prospective study of dose-escalated proton therapy for early-stage non-small cell lung cancer.
PubMed 文献 · Radiother Oncol · 2017-01-28

该Ⅰ/Ⅱ期前瞻性研究纳入35例不可手术的早期非小细胞肺癌(NSCLC)患者,给予87.5Gy、2.5Gy/次的质子治疗,中位随访83.1个月;5年总生存率28.1%,5年局部无复发率85.0%,远处转移率随T分期升高而显著增加,毒性可耐受。

要点

  • 87.5Gy质子治疗在不可手术早期NSCLC中耐受良好且有效
  • 5年总生存率28.1%,5年局部无复发生存率85.0%
  • T分期升高与远处转移率显著增加相关(p=0.006)

核心结论

  • 消融剂量质子治疗对不可手术早期NSCLC耐受良好且有效;T2和T3病变应考虑全身治疗以降低远处转移率。

研究设计与样本

  • 2006年6月至2011年9月开展的前瞻性Ⅰ/Ⅱ期研究,纳入35例不可手术T1N0M0(中央或上部位置,12例)或T2-3N0M0(任何位置,23例)NSCLC患者。

主要发现

  • 中位随访83.1个月(95%CI:69.2-97.1个月);1、3、5年总生存率分别为85.7%、42.9%、28.1%。
  • 5年局部无复发生存率85.0%,区域无复发生存率89.2%,远处无转移生存率54.4%。
  • 不同T分期对局部和区域复发无影响(p=0.499,p=1.00),但T分期升高时远处转移率显著增加(p=0.006)。
  • 最常见不良反应为皮炎(2级51.4%,3级2.9%)和放射性肺炎(2级11.4%,3级2.9%)。
  • 其他2级毒性包括食管炎(2.9%)、肋骨骨折(2.9%)、心脏毒性(5.7%)和胸壁疼痛(2.9%)。

关键数值与推荐

  • 质子治疗剂量为87.5Gy,2.5Gy/次;毒性按CTCAE 4.0版评分。

临床怎么用

  • 对不可手术早期NSCLC可采用消融剂量质子治疗,并密切监测远处转移,尤其T2、T3病变可考虑联合全身治疗。

局限性

  • 本研究为单臂Ⅰ/Ⅱ期前瞻性研究,样本量35例,未设对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this phase I/II study was to assess the long-term clinical benefits and toxicities of proton beam therapy for medically inoperable early-stage non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: From June 2006 to September 2011, 35 patients with medically inoperable T1N0M0 (central or superior location, 12 patients) or T2-3N0M0 (any location, 23 patients) NSCLC were treated with 87.5Gy at 2.5Gy/fraction of proton therapy. Toxicities were scored according to the Common Terminology Criteria for Adverse Events, version 4.0. RESULTS: The median follow-up time was 83.1months (95% CI: 69.2-97.1months). For all 35 patients, the 1, 3, and 5-year overall survival rates were 85.7%, 42.9%, and 28.1%, respectively. The 5-year local recurrence-free, regional recurrence-free, and distant metastasis-free survival rates were 85.0%, 89.2%, and 54.4%, respectively. Different T stages had no effect on local and regional recurrence (p=0.499, p=1.00). However, with the increase in T stages, the distant metastasis rate increased significantly (p=0.006). The most common adverse effects were dermatitis (grade 2, 51.4%; grade 3, 2.9%) and radiation pneumonitis (grade 2, 11.4%; grade 3, 2.9%). Other grade 2 toxicities included esophagitis (2.9%), rib fracture (2.9%), heart toxicities (5.7%), and chest wall pain (2.9%). CONCLUSIONS: According to our long-term follow-up data, proton therapy with ablative doses is well tolerated and effective in medically inoperable early-stage NSCLC. Systemic therapy should be considered to reduce the rate of distant metastasis in cases of T2 and T3 lesions.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Chang JY, Zhang W, Komaki R, et al. Long-term outcome of phase I/II prospective study of dose-escalated proton therapy for early-stage non-small cell lung cancer. Radiother Oncol. 2017. PMID: 28139305. doi:10.1016/j.radonc.2016.10.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。